Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071605 | 1.00 | AKR1C3 (0.45) | AKR1C3MAPTMEN1S1PR4LMNA | |
| SCHEMBL7071603 | 1.00 | AKR1C3 (0.45) | AKR1C3MAPTMEN1S1PR4LMNA | |
| SCHEMBL7072532 | 0.82 | NPFFR1 (0.39) | AKR1C3TP53 | |
| SCHEMBL7072526 | 0.82 | NPFFR1 (0.39) | AKR1C3TP53 | |
| SCHEMBL7067160 | 0.81 | ALDH1A1 (0.51) | AKR1C3MAPTMEN1LMNAKMT2A | |
| SCHEMBL7071034 | 0.81 | ALDH1A1 (0.51) | AKR1C3MAPTMEN1LMNAKMT2A | |
| SCHEMBL8387737 | 0.81 | KDM4E (0.53) | MEN1KMT2AGLO1KDM4E | |
| SCHEMBL8387734 | 0.81 | KDM4E (0.53) | MEN1KMT2AGLO1KDM4E | |
| SCHEMBL211524 | 0.80 | AKR1C3 (0.56) | AKR1C3MAPTMEN1LMNAMAPK1 | |
| SCHEMBL3716652 | 0.80 | AKR1C3 (0.56) | AKR1C3MAPTMEN1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
| WO-2002018354-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | TOP1, OXA1L, TK1 | AKR1C3 890/4885MAPT 2174/4885MEN1 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.